NCT05858164

Who might be able to join this trial:

• You must be 18 years of age or older at the time of signing the consent form.
• You must be able to understand and sign a consent form agreeing to take part in the trial.
• You must have a solid tumor cancer (not a brain or spinal cord cancer) that can be measured on a scan, as assessed by the trial team.
• You must be well enough to carry out daily activities with little to no limitation (as measured by a standard health scale used by doctors — confirm with trial site).
• You must have a solid tumor cancer that has been confirmed by a tissue sample (biopsy), and your cancer must have either stopped responding to available treatments, or those treatments are not suitable for you.
• Your tumor must have been tested using appropriate genetic or molecular tests before joining, in line with your country's guidelines.
• You must provide a stored tissue sample from your tumor at the start of the trial.
• You must be willing to have two biopsies (tissue samples taken from your tumor) — one before treatment starts and one during treatment.
• Your kidneys, liver, and other organs must be working well enough to take part (confirm with trial site).
• You must agree to use contraception during treatment and for at least 6 months after your last dose of the study treatment.

Who may not be able to join:

• You have previously received an organ or tissue transplant from another person.
• You have previously been treated with a type of drug called a DGK inhibitor (confirm with trial site).
• You previously received certain immunotherapy drugs (such as PD-1, PD-L1, or PD-L2 blockers, or similar treatments targeting the immune system) and had to stop because of a severe or life-threatening reaction related to your immune system.
• You have received cancer treatment (including experimental treatments) within the past 4 weeks, or within 5 half-lives of the drug — whichever is shorter, or certain growth-factor medicines within the past 4 weeks.
• You are still experiencing side effects from previous radiotherapy (radiation treatment), are taking steroid medicines to manage those effects, or have had radiation-related lung problems.
• You have had a blood transfusion within the 2 weeks before starting treatment.
• You have received a live vaccine within 30 days before your first dose of the study drug.
• You are currently taking part in, or have recently taken part in, another clinical trial using an experimental drug or device within the past 4 weeks.
• You have a condition that weakens your immune system, or you are taking steroid or other immune-suppressing medicines regularly within 7 days before starting the study drug.
• You have another cancer (separate from the one being treated in this trial) that is still growing or has needed treatment within the last 3 years.
• You have new cancer spread to the brain found on a scan at the start of the trial.
• Your cancer started in the brain or spinal cord, or has spread to the lining of the brain or spinal cord.
• You have a digestive condition (such as short bowel syndrome or a blockage in your bowel) that may affect how your body absorbs medicines taken by mouth, with ongoing symptoms in the last 6 months.
• You have an active autoimmune disease (such as inflammatory bowel disease) that has needed medical treatment in the past 2 years.
• You currently have lung inflammation (pneumonitis) or scarring of the lungs (interstitial lung disease).
• You have an active infection that requires treatment with medicines given throughout your body (such as antibiotics given by drip or tablet).

Important: Always verify eligibility with the trial site directly before applying.